{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:45:59Z","timestamp":1785843959013,"version":"3.56.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s10157-026-02874-1","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T07:21:53Z","timestamp":1778656913000},"page":"1101-1107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The amount of sodium intake may affect the susceptibility to treatment with mineralocorticoid receptor antagonists in patients with primary aldosteronism"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8114-8952","authenticated-orcid":false,"given":"Satoshi","family":"Kidoguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Sugano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruri","family":"Kawauchi-Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2874_CR1","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.3390\/ijms23094803","volume":"23","author":"F Bioletto","year":"2022","unstructured":"Bioletto F, Bollati M, Lopez C, Arata S, Procopio M, Ponzetto F, et al. Primary Aldosteronism and Resistant Hypertension: A Pathophysiological Insight. Int J Mol Sci. 2022;23:4803.","journal-title":"Int J Mol Sci"},{"key":"2874_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","volume":"9","author":"M Reincke","year":"2021","unstructured":"Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA. Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 2021;9:876\u201392.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2874_CR3","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1210\/clinem\/dgaf284","volume":"110","author":"GK Adler","year":"2025","unstructured":"Adler GK, Stowasser M, Correa RR, Khan N, Kline G, McGowan MJ, et al. Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2025;110:2453\u201395.","journal-title":"J Clin Endocrinol Metab"},{"key":"2874_CR4","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol. 2005;45:1243\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"2874_CR5","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6:41\u201350.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2874_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000015985","volume":"98","author":"X Wu","year":"2019","unstructured":"Wu X, Yu J, Tian H. Cardiovascular risk in primary aldosteronism: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98:e15985.","journal-title":"Medicine (Baltimore)"},{"key":"2874_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1507\/endocrj.EJ21-0508","volume":"69","author":"M Naruse","year":"2022","unstructured":"Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J. 2022;69:327\u201359.","journal-title":"Endocr J"},{"key":"2874_CR8","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"2874_CR9","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.2174\/1381612825666190311130138","volume":"24","author":"K Stavropoulos","year":"2018","unstructured":"Stavropoulos K, Papadopoulos C, Koutsampasopoulos K, Lales G, Mitas C, Doumas M. Mineralocorticoid receptor antagonists in primary aldosteronism. Curr Pharm Des. 2018;24:5508\u201316.","journal-title":"Curr Pharm Des"},{"key":"2874_CR10","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41440-020-00570-5","volume":"44","author":"F Satoh","year":"2021","unstructured":"Satoh F, Ito S, Itoh H, Rakugi H, Shibata H, Ichihara A, et al. Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism. Hypertens Res. 2021;44:464\u201372.","journal-title":"Hypertens Res"},{"key":"2874_CR11","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/nrendo.2014.139","volume":"10","author":"HS Narula","year":"2014","unstructured":"Narula HS, Carlson HE. Gynaecomastia--pathophysiology, diagnosis and treatment. Nat Rev Endocrinol. 2014;10:684\u201398.","journal-title":"Nat Rev Endocrinol"},{"key":"2874_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41440-019-0244-4","volume":"42","author":"M Satoh","year":"2019","unstructured":"Satoh M, Maruhashi T, Yoshida Y, Shibata H. Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism. Hypertens Res. 2019;42:817\u201324.","journal-title":"Hypertens Res"},{"key":"2874_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/ajh.2010.169","volume":"23","author":"LA Sechi","year":"2010","unstructured":"Sechi LA, Colussi G, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens. 2010;23:1253\u201360.","journal-title":"Am J Hypertens"},{"key":"2874_CR14","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1161\/HYPERTENSIONAHA.113.01316","volume":"62","author":"GP Rossi","year":"2013","unstructured":"Rossi GP, Cesari M, Cuspidi C, Maiolino G, Cicala MV, Bisogni V, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62:62\u20139.","journal-title":"Hypertension"},{"key":"2874_CR15","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1530\/EJE-22-0375","volume":"187","author":"SY Chen","year":"2022","unstructured":"Chen SY, Chen JY, Huang WC, Puar THK, Chin Kek P, Chueh JS, et al. Cardiovascular outcomes and all-cause mortality in primary aldosteronism after adrenalectomy or mineralocorticoid receptor antagonist treatment: a meta-analysis. Eur J Endocrinol. 2022;187:S47\u201358.","journal-title":"Eur J Endocrinol"},{"key":"2874_CR16","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","volume":"6","author":"GL Hundemer","year":"2018","unstructured":"Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6:51\u20139.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2874_CR17","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","volume":"3","author":"GL Hundemer","year":"2018","unstructured":"Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism. JAMA Cardiol. 2018;3:768\u201374.","journal-title":"JAMA Cardiol"},{"key":"2874_CR18","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1161\/HYPERTENSIONAHA.123.21096","volume":"80","author":"S Katsuragawa","year":"2023","unstructured":"Katsuragawa S, Goto A, Shinoda S, Inoue K, Nakai K, Saito J, et al. Association of reversal of renin suppression with long-term renal outcome in medically treated primary aldosteronism. Hypertension. 2023;80:1909\u201320.","journal-title":"Hypertension"},{"key":"2874_CR19","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1093\/ajh\/6.9.780","volume":"6","author":"AM Sharma","year":"1993","unstructured":"Sharma AM, Schorr U, Oelkers W, Distler A. Effects of sodium salts on plasma renin activity and norepinephrine response to orthostasis in salt-sensitive normotensive subjects. Am J Hypertens. 1993;6:780\u20135.","journal-title":"Am J Hypertens"},{"key":"2874_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41440-022-01045-5","volume":"46","author":"Y Yoshida","year":"2023","unstructured":"Yoshida Y, Fujiki R, Kinoshita M, Sada K, Miyamoto S, Ozeki Y, et al. Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: The potential importance of post-treatment plasma renin levels. Hypertens Res. 2023;46:100\u20137.","journal-title":"Hypertens Res"},{"key":"2874_CR21","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/s41440-022-01155-0","volume":"46","author":"K Sawami","year":"2023","unstructured":"Sawami K, Tanaka A, Node K. Appropriate mineralocorticoid receptor antagonism and salt restriction are essential for primary aldosteronism therapy. Hypertens Res. 2023;46:794\u20136.","journal-title":"Hypertens Res"},{"key":"2874_CR22","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1038\/s41440-025-02270-4","volume":"48","author":"X Bu","year":"2025","unstructured":"Bu X, Sun F, Li Q, Zhang H, Jiang N, Luo Y, et al. High salt intake exacerbates aldosterone-related target organ damage in patients with primary aldosteronism. Hypertens Res. 2025;48:2339\u201348.","journal-title":"Hypertens Res"},{"key":"2874_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1124479","volume":"14","author":"L Zhou","year":"2023","unstructured":"Zhou L, Jiang Y, Zhang C, Su T, Jiang L, Zhou W, et al. Effects of a low-sodium diet in patients with idiopathic hyperaldosteronism: a randomized controlled trial. Front Endocrinol (Lausanne). 2023;14:1124479.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2874_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/1470320319870891","volume":"20","author":"S Kidoguchi","year":"2019","unstructured":"Kidoguchi S, Sugano N, Hayashi-Ishikawa N, Morisawa N, Tokudome G, Yokoo T. The characteristics of captopril challenge test-positive patients using various criteria. J Renin Angiotensin Aldosterone Syst. 2019;20:1470320319870891.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2874_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/1470320320919610","volume":"21","author":"S Kidoguchi","year":"2020","unstructured":"Kidoguchi S, Sugano N, Kawauchi R, Nakashima D, Hayashi-Ishikawa N, Tokudome G, et al. Evaluation of various confirmatory tests for the diagnosis of aldosterone-producing adenoma. J Renin Angiotensin Aldosterone Syst. 2020;21:1470320320919610.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2874_CR26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/sj.jhh.1001307","volume":"16","author":"T Tanaka","year":"2002","unstructured":"Tanaka T, Okamura T, Miura K, Kadowaki T, Ueshima H, Nakagawa H, et al. A simple method to estimate population 24-h urinary sodium and potassium excretion using a casual urine specimen. J Hum Hypertens. 2002;16:97\u2013103.","journal-title":"J Hum Hypertens"},{"key":"2874_CR27","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study). Hypertension. 2020;75:51\u20138.","journal-title":"Hypertension"},{"key":"2874_CR28","doi-asserted-by":"publisher","first-page":"204062232211432","DOI":"10.1177\/20406223221143233","volume":"14","author":"CW Liao","year":"2023","unstructured":"Liao CW, Lin YT, Tsai CH, Chang YY, Chen ZW, Lu CC, et al. Mineralocorticoid receptor antagonist treatment improved arterial stiffness in patients with primary aldosteronism: a cohort study compared with adrenalectomy. Ther Adv Chronic Dis. 2023;14:20406223221143230.","journal-title":"Ther Adv Chronic Dis"},{"key":"2874_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/archinternmed.2007.33","volume":"168","author":"C Catena","year":"2008","unstructured":"Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, et al. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med. 2008;168:80\u20135.","journal-title":"Arch Intern Med"},{"key":"2874_CR30","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1210\/js.2019-00019","volume":"3","author":"YY Chen","year":"2019","unstructured":"Chen YY, Lin YH, Huang WC, Chueh E, Chen L, Yang SY, et al. Adrenalectomy Improves the Long-Term Risk of End-Stage Renal Disease and Mortality of Primary Aldosteronism. J Endocr Soc. 2019;3:1110\u201326.","journal-title":"J Endocr Soc"},{"key":"2874_CR31","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1210\/clinem\/dgac649","volume":"108","author":"ZW Chen","year":"2023","unstructured":"Chen ZW, Pan CT, Liao CW, Tsai CH, Chang YY, Chang CC, et al. Implication of MR Activity in Posttreatment Arterial Stiffness Reversal in Patients With Primary Aldosteronism. J Clin Endocrinol Metab. 2023;108:624\u201332.","journal-title":"J Clin Endocrinol Metab"},{"key":"2874_CR32","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1097\/HJH.0000000000004030","volume":"43","author":"S Kishimoto","year":"2025","unstructured":"Kishimoto S, Maruhashi T, Kajikawa M, Mizobuchi A, Harada T, Yamaji T, et al. Chronic Esaxerenone treatment improves vascular function and lowers peripheral arterial stiffness in patients with idiopathic hyperaldosteronism. J Hypertens. 2025;43:1205\u201313.","journal-title":"J Hypertens"},{"key":"2874_CR33","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1161\/HYPERTENSIONAHA.123.21895","volume":"80","author":"E Gkaniatsa","year":"2023","unstructured":"Gkaniatsa E, Zverkova Sandstr\u00f6m T, Rosengren A, Trimpou P, Olsson DS, Lind M, et al. Mortality in patients with primary aldosteronism: A Swedish nationwide study. Hypertension. 2023;80:2601\u201310.","journal-title":"Hypertension"},{"key":"2874_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.625457","volume":"12","author":"Y Tezuka","year":"2021","unstructured":"Tezuka Y, Turcu AF. Real-world effectiveness of mineralocorticoid receptor antagonists in primary aldosteronism. Front Endocrinol (Lausanne). 2021;12:625457.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2874_CR35","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1210\/jc.2016-1963","volume":"101","author":"R Baudrand","year":"2016","unstructured":"Baudrand R, Guarda FJ, Torrey J, Williams G, Vaidya A. Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism. J Clin Endocrinol Metab. 2016;101:3989\u201396.","journal-title":"J Clin Endocrinol Metab"},{"key":"2874_CR36","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/joim.13618","volume":"294","author":"H Schneider","year":"2023","unstructured":"Schneider H, Sarkis AL, Sturm L, Britz V, Lechner A, Potzel AL, et al. Moderate dietary salt restriction improves blood pressure and mental well-being in patients with primary aldosteronism: the salt CONNtrol trial. J Intern Med. 2023;294:47\u201357.","journal-title":"J Intern Med"},{"key":"2874_CR37","doi-asserted-by":"publisher","first-page":"1136574","DOI":"10.3389\/fphys.2023.1136574","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang Z, Zhao X, Bu L, Liu K, Li Z, Zhang H, et al. Low sodium intake ameliorates hypertension and left ventricular hypertrophy in mice with primary aldosteronism. Front Physiol. 2023;14:1136574.","journal-title":"Front Physiol"},{"key":"2874_CR38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/hr.2013.124","volume":"37","author":"T Hattori","year":"2014","unstructured":"Hattori T, Murase T, Sugiura Y, Nagasawa K, Takahashi K, Ohtake M, et al. Effects of salt status and blockade of mineralocorticoid receptors on aldosterone-induced cardiac injury. Hypertens Res. 2014;37:125\u201333.","journal-title":"Hypertens Res"},{"key":"2874_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-020-1023-y","volume":"22","author":"D Sueta","year":"2020","unstructured":"Sueta D, Yamamoto E, Tsujita K. Mineralocorticoid receptor blockers: novel selective nonsteroidal mineralocorticoid receptor antagonists. Curr Hypertens Rep. 2020;22:21.","journal-title":"Curr Hypertens Rep"},{"key":"2874_CR40","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1210\/clinem\/dgac568","volume":"108","author":"E Ng","year":"2022","unstructured":"Ng E, Gwini SM, Libianto R, Choy KW, Lu ZX, Shen J, et al. Aldosterone, renin, and aldosterone-to-renin ratio variability in screening for primary aldosteronism. J Clin Endocrinol Metab. 2022;108:33\u201341.","journal-title":"J Clin Endocrinol Metab"},{"key":"2874_CR41","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1161\/HYPERTENSIONAHA.119.13833","volume":"74","author":"F Buffolo","year":"2019","unstructured":"Buffolo F, Li Q, Monticone S, Heinrich DA, Mattei A, Pieroni J, et al. Primary aldosteronism and obstructive sleep apnea: A cross-sectional multi-ethnic study. Hypertension. 2019;74:1532\u201340.","journal-title":"Hypertension"},{"key":"2874_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/jsr.13726","volume":"32","author":"HH Loh","year":"2023","unstructured":"Loh HH, Lim QH, Chai CS, Goh SL, Lim LL, Yee A, et al. Influence and implications of the renin-angiotensin-aldosterone system in obstructive sleep apnea: An updated systematic review and meta-analysis. J Sleep Res. 2023;32:e13726.","journal-title":"J Sleep Res"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02874-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-026-02874-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-026-02874-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:16:11Z","timestamp":1785842171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-026-02874-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2874"],"URL":"https:\/\/doi.org\/10.1007\/s10157-026-02874-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"21 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Original article has been corrected to update reference list.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}